ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives

References

• Geetha D, Jefferson JA. ANCA-Associated Vasculitis: core Curriculum 2020. Am J Kidney Dis. 2020;75(1):124–137. doi:10.1053/j.ajkd.2019.04.031
   PubMed Web of Science ®Google Scholar
• Fries JF, Hunder GG, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum. 1990;33:1135–1136. doi:10.1002/art.1780330812
   PubMed Web of Science ®Google Scholar
• van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet. 1985;1(8426):425–429. doi:10.1016/S0140-6736(85)91147-X
   PubMed Web of Science ®Google Scholar
• Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol. 2013;17(5):603–606. doi:10.1007/s10157-013-0869-6
   PubMed Web of Science ®Google Scholar
• Cornec D, Cornec-le Gall E, Fervenza FC, Specks U. ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol. 2016;12(10):570–579. doi:10.1038/nrrheum.2016.123
   PubMed Web of Science ®Google Scholar
• Li W, Huang H, Cai M, Yuan T, Sheng Y. Antineutrophil cytoplasmic antibody-associated vasculitis update: genetic pathogenesis. Front Immunol. 2021;26(12):970.
   Google Scholar
• Merkel PA, Xie G, Monach PA, et al.; for Vasculitis Clinical Research Consortium. Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Rheumatol. 2017;69(5):1054–1066. doi:10.1002/art.40034
   PubMed Web of Science ®Google Scholar
• Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367(3):214–223. doi:10.1056/NEJMoa1108735
   PubMed Web of Science ®Google Scholar
• Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J. 1982;285(6342):606. doi:10.1136/bmj.285.6342.606
   PubMed Web of Science ®Google Scholar
• Popa ER, Stegeman CA, Abdulahad WH, et al. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener’s granulomatosis. Rheumatology. 2007;46(6):1029–1033. doi:10.1093/rheumatology/kem022
   PubMed Web of Science ®Google Scholar
• Gómez-Puerta JA, Gedmintas L, Costenbader KH. The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis. Autoimmun Rev. 2013;12(12):1129–1135. doi:10.1016/j.autrev.2013.06.016
   PubMed Web of Science ®Google Scholar
• Lane SE, Watts RA, Bentham G, Innes NJ, Scott DGI. Are environmental factors important in primary systemic vasculitis? A case–control study. Arthritis Rheum. 2003;48(3):814–823. doi:10.1002/art.10830
   PubMed Web of Science ®Google Scholar
• Giorgiutti S, Dieudonne Y, Hinschberger O, et al. Prevalence of antineutrophil cytoplasmic antibody-associated vasculitis and spatial association with quarries in a region of northeastern France: a capture-recapture and geospatial analysis. Arthritis Rheumatol. 2021;73:2078–2085. doi:10.1002/art.41767
   PubMed Web of Science ®Google Scholar
• Dobre M, Wish J, Negrea L. Hydralazine-induced ANCA-positive pauci-immune glomerulonephritis: a case report and literature review. Ren Fail. 2009;31(8):745–748. doi:10.3109/08860220903118590
   PubMed Web of Science ®Google Scholar
• Sethi S, Sahani M, Oei LS. ANCA-positive crescentic glomerulonephritis associated with minocycline therapy. Am J Kidney Dis. 2003;42(2):E27–31. doi:10.1016/S0272-6386(03)00671-1
   PubMed Web of Science ®Google Scholar
• Dolman KM, Gans RO, Vervaat TJ, et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet. 1993;342(8872):651–652. doi:10.1016/0140-6736(93)91761-A
   PubMed Web of Science ®Google Scholar
• Jin Q, Kant S, Alhariri J, Geetha D. Levamisole adulterated cocaine associated ANCA vasculitis: review of literature and update on pathogenesis. J Community Hosp Intern Med Perspect. 2018;8(6):339–344. doi:10.1080/20009666.2018.1536242
   PubMed Web of Science ®Google Scholar
• Nakazawa D, Tomaru U, Suzuki A, et al. Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64(11):3779–3787. doi:10.1002/art.34619
   PubMed Web of Science ®Google Scholar
• Takeuchi Y, Saito A, Ojima Y, et al. The influence of the Great East Japan earthquake on microscopic polyangiitis: a retrospective observational study. PLoS One. 2017;12(5):e0177482. doi:10.1371/journal.pone.0177482
   PubMed Web of Science ®Google Scholar
• McDermott G, Fu X, Stone JH, et al. Association of cigarette smoking with antineutrophil cytoplasmic antibody-associated vasculitis. JAMA Intern Med. 2020;180(6):870–876. doi:10.1001/jamainternmed.2020.0675
   PubMed Web of Science ®Google Scholar
• Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis: EC/BCR Project for ANCA Assay Standardization. Kidney Int. 1998;53:743–745. doi:10.1046/j.1523-1755.1998.00807.x
   PubMed Web of Science ®Google Scholar
• Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem. 2006;52(2):171–181. doi:10.1373/clinchem.2005.058560
   PubMed Web of Science ®Google Scholar
• Weiner M, Segelmark M. The clinical presentation and therapy of diseases related to anti-neutrophil cytoplasmic antibodies (ANCA). Autoimmun Rev. 2016;15(10):978–982. doi:10.1016/j.autrev.2016.07.016
   PubMed Web of Science ®Google Scholar
• Philipponnet C, Garrouste C, Le Guenno G, et al. Antineutrophilic cytoplasmic antibody-associated vasculitis and malignant hemopathies, a retrospective study of 16 cases. Joint Bone Spine. 2017;84(1):51–57. doi:10.1016/j.jbspin.2016.01.012
   PubMed Web of Science ®Google Scholar
• Little MA, Smyth L, Salama AD, et al. Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. Am J Pathol. 2009;174(4):1212–1220. doi:10.2353/ajpath.2009.080458
   PubMed Web of Science ®Google Scholar
• Little MA, Al-Ani B, Ren S, et al. Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system. PLoS One. 2012;7(1):e28626. doi:10.1371/journal.pone.0028626
   PubMed Web of Science ®Google Scholar
• Roth AJ, Ooi JD, Hess JJ, et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest. 2013;123(4):1773–1783. doi:10.1172/JCI65292
   PubMed Web of Science ®Google Scholar
• von Borstel A, Sanders JS, Rutgers A, Stegeman CA, Heeringa P, Abdulahad WH. Cellular immune regulation in the pathogenesis of ANCA-associated vasculitides. Autoimmunity Rev. 2018;17(4):413–421. doi:10.1016/j.autrev.2017.12.002
   PubMed Web of Science ®Google Scholar
• Nakazawa D, Shida H, Tomaru U, et al. Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA–associated microscopic polyangiitis. J Am Soc Nephrol. 2014;25(5):990–997. doi:10.1681/ASN.2013060606
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–1535. doi:10.1126/science.1092385
   PubMed Web of Science ®Google Scholar
• Kessenbrock K, Krumbholz M, Schonermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15(6):623–625. doi:10.1038/nm.1959
   PubMed Web of Science ®Google Scholar
• Sangaletti S, Tripodo C, Chiodoni C, et al. Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood. 2012;11(120):3007–3018. doi:10.1182/blood-2012-03-416156
   Web of Science ®Google Scholar
• Saffarzadeh M, Juenemann C, Queisser MA, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS One. 2012;7(2):e32366. doi:10.1371/journal.pone.0032366
   PubMed Web of Science ®Google Scholar
• Tsukui D, Kimura Y, Kono H. Pathogenesis and pathology of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. J Transl Autoimmun. 2021;4:100094. doi:10.1016/j.jtauto.2021.100094
   PubMedGoogle Scholar
• Jennette JC, Wilkman AS, Falk RJ. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol. 1989;135(5):921–930.
   PubMed Web of Science ®Google Scholar
• Jennette JC. Implications for pathogenesis of patterns of injury in small-and medium-sized-vessel vasculitis. Cleve Clin J Med. 2002;69(Suppl2):SII33–8. doi:10.3949/ccjm.69.Suppl_2.SII33
   PubMed Web of Science ®Google Scholar
• Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol. 2007;170(1):52–64. doi:10.2353/ajpath.2007.060573
   PubMed Web of Science ®Google Scholar
• Chen M, Jayne DRW, Zhao M-H. Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat Rev Nephrol. 2017;13(6):359–367. doi:10.1038/nrneph.2017.37
   PubMed Web of Science ®Google Scholar
• Xiao H, Dairaghi DJ, Powers JP, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol. 2014;25(2):225–231. doi:10.1681/ASN.2013020143
   PubMed Web of Science ®Google Scholar
• Jayne DR, Bruchfeld AN, Harper L, et al.; for CLEAR Study Group. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28(9):2756–2767. doi:10.1681/ASN.2016111179
   PubMed Web of Science ®Google Scholar
• Jayne DR, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599–609. doi:10.1056/NEJMoa2023386
   PubMed Web of Science ®Google Scholar
• Chen SF, Wang FM, Li ZY, Yu F, Zhao MH, Chen M. Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis. Arthritis Res Ther. 2015;17(1):129. doi:10.1186/s13075-015-0656-8
   PubMed Web of Science ®Google Scholar
• Chen SF, Wang FM, Li ZY, Yu F, Chen M, Zhao MH. Complement factor H inhibits anti-neutrophil cytoplasmic autoantibody-induced neutrophil activation by interacting with neutrophils. Front Immunol. 2018;19(9):559. doi:10.3389/fimmu.2018.00559
   Web of Science ®Google Scholar
• Antonelou M, Michaëlsson E, Evans RDR, et al; for RAVE-ITN Investigators. Therapeutic myeloperoxidase inhibition attenuates neutrophil activation, ANCA-mediated endothelial damage, and crescentic GN. J Am Soc Nephrol. 2020;31(2):350–364. doi:10.1681/ASN.2019060618
   PubMed Web of Science ®Google Scholar
• McAdoo SP, Prendecki M, Tanna A, et al. Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model. Kidney Int. 2020;97(6):1196–1207. doi:10.1016/j.kint.2019.12.014
   PubMed Web of Science ®Google Scholar
• Berti A, Warner R, Johnson K, et al; for RAVE-ITN Research Group. Brief report: circulating cytokine profiles and antineutrophil cytoplasmic antibody specificity in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2018;70(7):1114–1121. doi:10.1002/art.40471
   PubMed Web of Science ®Google Scholar
• Abdulahad WH, Stegeman CA, Kallenberg CGM. Review article: the role of CD4+ T cells in ANCA-associated systemic vasculitis. Nephrology. 2009;14(1):26–32. doi:10.1111/j.1440-1797.2008.01069.x
   PubMed Web of Science ®Google Scholar
• Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med. 1998;129(5):345–352. doi:10.7326/0003-4819-129-5-199809010-00001
   PubMed Web of Science ®Google Scholar
• Mohammad AJ. An update on the epidemiology of ANCA-associated vasculitis. Rheumatology. 2020;59(Suppl 3):iii42–iii50. doi:10.1093/rheumatology/keaa089
   PubMed Web of Science ®Google Scholar
• Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000;43(2):414–419. doi:10.1002/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0
   PubMed Web of Science ®Google Scholar
• Pearce FA, Lanyon PC, Grainge MJ, et al. Incidence of ANCA-associated vasculitis in a UK mixed ethnicity population. Rheumatology. 2016;55(9):1656–1663. doi:10.1093/rheumatology/kew232
   PubMed Web of Science ®Google Scholar
• Watts RA, Gonzalez-Gay MA, Lane SE, Garcia-Porrua C, Bentham G, Scott DG. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis. 2001;60(2):170–172. doi:10.1136/ard.60.2.170
   PubMed Web of Science ®Google Scholar
• Pearce FA, Craven A, Merkel PA, Luqmani RA, Watts RA. Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology. 2017;56(11):1962–1969. doi:10.1093/rheumatology/kex293
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Watts RA, Kobayashi S, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the. U K Rheumatology. 2011;50(10):1916–1920. doi:10.1093/rheumatology/ker205
   PubMed Web of Science ®Google Scholar
• Li J, Cui Z, Long JY, et al. The frequency of ANCA-associated vasculitis in a national database of hospitalized patients in China. Arthritis Res Ther. 2018;20(1):226. doi:10.1186/s13075-018-1708-7
   PubMed Web of Science ®Google Scholar
• Weiner M, Bjørneklett R, Hrušková Z, et al. Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. Nephrol Dial Transplant. 2019;34(2):301–308. doi:10.1093/ndt/gfy106
   PubMed Web of Science ®Google Scholar
• Draibe J, Rodó X, Fulladosa X, et al.; for GLOMCAT. Seasonal variations in the onset of positive and negative renal ANCA-associated vasculitis in Spain. Clin Kidney J. 2018;11(4):468–473. doi:10.1093/ckj/sfx127
   PubMed Web of Science ®Google Scholar
• Monti S, Craven A, Klersy C, et al. Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. Rheumatology. 2021;60(2):617–628. doi:10.1093/rheumatology/keaa215
   PubMed Web of Science ®Google Scholar
• Miloslavsky EM, Lu N, Unizony S, et al. Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive and ANCA-negative patients with granulomatosis with polyangiitis (Wegener’s): distinct patient subsets. Arthritis Rheumatol. 2016;68(12):2945–2952. doi:10.1002/art.39812
   PubMed Web of Science ®Google Scholar
• Schirmer JH, Wright MN, Herrmann K, et al. Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive granulomatosis with polyangiitis (Wegener’s) is a clinically distinct subset of ANCA-associated vasculitis: a retrospective analysis of 315 patients from a German vasculitis referral center. Arthritis Rheumatol. 2016;68(12):2953–2963. doi:10.1002/art.39786
   PubMed Web of Science ®Google Scholar
• Chang DY, Li ZY, Chen M, Zhao MH. Myeloperoxidase-ANCA-positive granulomatosis with polyangiitis is a distinct subset of ANCA-associated vasculitis: a retrospective analysis of 455 patients from a single center in China. Semin Arthritis Rheum. 2019;48(4):701–706. doi:10.1016/j.semarthrit.2018.05.003
   PubMed Web of Science ®Google Scholar
• Aljuhani M, Makati D, Hoff A, et al. Antibody subtypes and titers predict clinical outcomes in ANCA-associated vasculitis. Rheumatol Int. 2021;41(5):965–972. doi:10.1007/s00296-021-04802-w
   PubMed Web of Science ®Google Scholar
• Berti A, Cornec-le Gall E, Cornec D, et al. Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. Nephrol Dial Transplant. 2019;34(9):1508–1517. doi:10.1093/ndt/gfy250
   PubMed Web of Science ®Google Scholar
• Solans-Laqué R, Fraile G, Rodriguez-Carballeira M, et al. Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity. Medicine. 2017;96(8):e6083. doi:10.1097/MD.0000000000006083
   PubMed Web of Science ®Google Scholar
• Micheletti RG, Chiesa Fuxench Z, Craven A, Watts RA, Luqmani RA, Merkel PA; for DCVAS Investigators. Cutaneous manifestations of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2020;72(10):1741–1747. doi:10.1002/art.41310
   PubMed Web of Science ®Google Scholar
• Frumholtz L, Laurent-Roussel S, Aumaître O, et al.; for French Vasculitis Study Group. Clinical and pathological significance of cutaneous manifestations in ANCA-associated vasculitides. Autoimmun Rev. 2017; 16(11):1138–1146. doi:10.1016/j.autrev.2017.09.009
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Mortensen KH, Babar J, et al. Pulmonary involvement in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: the influence of ANCA subtype. J Rheumatol. 2017;44(10):1458–1467. doi:10.3899/jrheum.161224
   PubMed Web of Science ®Google Scholar
• Néel A, Espitia-Thibault A, Arrigoni PP, et al. Bronchiectasis is highly prevalent in anti-MPO ANCA-associated vasculitis and is associated with a distinct disease presentation. Semin Arthritis Rheum. 2018;48(1):70–76. doi:10.1016/j.semarthrit.2017.12.002
   PubMed Web of Science ®Google Scholar
• Pearce FA, Lanyon PC, Watts RA, et al. Novel insights into the aetiology of granulomatosis with polyangiitis-a case-control study using the clinical practice research datalink. Rheumatology. 2018;57(6):1002–1010. doi:10.1093/rheumatology/kex512
   PubMed Web of Science ®Google Scholar
• Scherlinger M, Mertz P, Sagez F, et al. Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014. Autoimmun Rev. 2020;19(6):102531. doi:10.1016/j.autrev.2020.102531
   PubMed Web of Science ®Google Scholar
• Tan JA, Dehghan N, Chen W, Xie H, Esdaile JM, Avina-Zubietaa JA. Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies. Ann Rheum Dis. 2017;76(9):1566–1574. doi:10.1136/annrheumdis-2016-210942
   PubMed Web of Science ®Google Scholar
• Wallace ZS, Fu X, Harkness T, Stone JH, Zhang Y, Choi H. All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type. Rheumatology. 2020;59(9):2308–2315. doi:10.1093/rheumatology/kez589
   PubMed Web of Science ®Google Scholar
• Houben E, Penne EL, Voskuyl AE, et al. Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies. Rheumatology. 2018;57(3):555–562. doi:10.1093/rheumatology/kex338
   PubMed Web of Science ®Google Scholar
• Knight A, Askling J, Granath F, Sparen P, Ekbom A. Urinary bladder cancer in Wegener’s granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis. 2004;63(10):1307–1311. doi:10.1136/ard.2003.019125
   PubMed Web of Science ®Google Scholar
• Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008;35(1):100–105.
   PubMed Web of Science ®Google Scholar
• van Daalen EE, Rizzo R, Kronbichler A, et al. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis. 2017;76(6):1064–1069. doi:10.1136/annrheumdis-2016-209925
   PubMed Web of Science ®Google Scholar
• Holle JU, Gross WL, Latza U, et al. Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 2011;63(1):257–266. doi:10.1002/art.27763
   PubMed Web of Science ®Google Scholar
• Heijl C, Westman K, Höglund P, Mohammad AJ. Malignancies in patients with antineutrophil cytoplasmic antibody-associated vasculitis: a population-based cohort study. J Rheumatol. 2020;47(8):1229–1237. doi:10.3899/jrheum.181438
   PubMed Web of Science ®Google Scholar
• Choi ST, Ahn SV, Lee PH, Moon CM. The cancer risk according to three subtypes of ANCA-associated vasculitis: a propensity score-matched analysis of a nationwide study. Semin Arthritis Rheum. 2021;51(4):692–699. doi:10.1016/j.semarthrit.2021.03.014
   PubMed Web of Science ®Google Scholar
• Englund M, Merkel PA, Tomasson G, Segelmark M, Mohammad AJ. Comorbidities in patients with antineutrophil cytoplasmic antibody-associated vasculitis versus the general population. J Rheumatol. 2016;43(8):1553–1558. doi:10.3899/jrheum.151151
   PubMed Web of Science ®Google Scholar
• Liapi M, Jayne D, Merkel PA, Segelmark M, Mohammad AJ. Venous thromboembolism in ANCA-associated vasculitis. A population-based cohort study. Rheumatology. 2021;60(10):4616–4623. doi:10.1093/rheumatology/keab057
   PubMed Web of Science ®Google Scholar
• Moiseev S, Kronbichler A, Makarov E, et al. Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. Rheumatology. 2021;60(10):4654–4661. doi:10.1093/rheumatology/keab071
   PubMed Web of Science ®Google Scholar
• Kambas K, Chrysanthopoulou A, Vassilopoulos D, et al. Tissue factor expression in neutrophil extracellular traps and neutrophil derived macroparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. Ann Rheum Dis. 2014;73(10):1854–1863. doi:10.1136/annrheumdis-2013-203430
   PubMed Web of Science ®Google Scholar
• Sreih A, Cronin K, Shaw DG, et al. Diagnostic delays in vasculitis and factors associated with time to diagnosis. Orphanet J Rare Dis. 2021;16(1):184. doi:10.1186/s13023-021-01794-5
   PubMed Web of Science ®Google Scholar
• Yates M, Watts RA, Bajema IM, et al. EULAR/ ERA-EDTA recommendations for the management of ANCA associated vasculitis. Ann Rheum Dis. 2016;75(9):1583–1594. doi:10.1136/annrheumdis-2016-209133
   PubMed Web of Science ®Google Scholar
• Damoiseaux J, Csernok E, Rasmussen N, et al. Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays. Ann Rheum Dis. 2017;76(4):647–653. doi:10.1136/annrheumdis-2016-209507
   PubMed Web of Science ®Google Scholar
• Moiseev S, Cohen tervaert JW, Arimura Y, et al. 2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmun Rev. 2020;19(9):102618. doi:10.1016/j.autrev.2020.102618
   PubMed Web of Science ®Google Scholar
• Assarod K, Bostad L, Hammerstrom J, Jorstad S, Iverson BM. Renal histopathology and clinical course in 94 patients with Wegener's Granulomatosis. Nephrol Dial Transplant. 2001;16(5):953–960. doi:10.1093/ndt/16.5.953
   PubMed Web of Science ®Google Scholar
• Schnabel A, Holl-Ulrich K, Dalhoff K, Reuter M, Gross WL. Efficacy of transbronchial biopsy in pulmonary vasculitides. Eur Respir J. 1997;10(12):2738–2743. doi:10.1183/09031936.97.10122738
   PubMed Web of Science ®Google Scholar
• Padoan R, Campaniello D, Felicetti M, Cazzador D, Schiavon F. Ear, nose and throat in ANCA-associated vasculitis: a comprehensive review. Vessel Plus. 2021;5:41.
   Google Scholar
• Hunder GG, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum. 1990;33(8):1065–1067. doi:10.1002/art.1780330802
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Ringold S, Khanna D, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res. 2015;67(7):891–897. doi:10.1002/acr.22583
   Web of Science ®Google Scholar
• June RR, Aggarwal R. The use and abuse of diagnostic/classification criteria. Best Pract Res Clin Rheumatol. 2014;28(6):921–934. doi:10.1016/j.berh.2015.04.004
   PubMed Web of Science ®Google Scholar
• Basu N, Watts R, Bajema I, et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis. 2010;69(10):1744–1750. doi:10.1136/ard.2009.119032
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of the systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187–192. doi:10.1002/art.1780370206
   PubMed Web of Science ®Google Scholar
• Sinicio RA, Radice A. Antineutrophil cytoplasmic antibodies (ANCA) testing: detection methods and clinical application. Clin Exp Rheumatol. 2014;32(3 Suppl 82):S112–7.
   Google Scholar
• Seeliger B, Sznajd RJC. Are the 1990 American College of Rheumatology classification criteria still valid? Rheumatology. 2017;56(7):1154–1161. doi:10.1093/rheumatology/kex075
   PubMed Web of Science ®Google Scholar
• Craven A, Robson J, Ponte C, et al. ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clin Exp Nephrol. 2013;17(5):619–621. doi:10.1007/s10157-013-0854-0
   PubMed Web of Science ®Google Scholar
• Available from: https://research.ndorms.ox.ac.uk/public/dcvas/index.php. Accessed March 5, 2022.
   Google Scholar
• Suppiah R, Robson JC, Grayson PC, et al.2022 American College of Rheumatology/ European Alliance of Associations for Rheumatology classification criteria for microscopic polyangitis. Arthritis & Rheumatology. 2022 Mar; 74(3):400-6.
   Google Scholar
• Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Arthritis & Rheumatology. 2022 Mar; 74(3):386-92.
   Google Scholar
• Robson JC,Grayson PC, Ponte C, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Arthritis & Rheumatology. 2022 Mar;74(3):393-9.
   Google Scholar
• Jones RB, Furuta S, Tervaert JWC, et al; for European Vasculitis Society (EUVAS). Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis. 2015;74(6):1178–1182. doi:10.1136/annrheumdis-2014-206404
   PubMed Web of Science ®Google Scholar
• Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheumatol. 2021;73(8):1088–1105. doi:10.1002/acr.24634
   PubMed Web of Science ®Google Scholar
• Smith RM, Jones RB, Specks U, et al. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis. 2020;79(9):1243–1249. doi:10.1136/annrheumdis-2019-216863
   PubMed Web of Science ®Google Scholar
• Jayne D, Rasmussen N, Andrassy K, et al.; for European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36–44. doi:10.1056/NEJMoa020286
   PubMed Web of Science ®Google Scholar
• Waki D, Nishimura K, Tokumasu H, et al. Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective observational study. Medicine. 2020;99(8):e19173. doi:10.1097/MD.0000000000019173
   PubMed Web of Science ®Google Scholar
• Chanouzas D, McGregor JA, Nightingale P, et al. Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated vasculitis: a multi-center retrospective cohort study. BMC Nephrol. 2019;20(1):1–8. doi:10.1186/s12882-019-1226-0
   PubMed Web of Science ®Google Scholar
• Walsh M, Merkel PA, Peh C-A, et al; for PEXIVAS Investigators. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622–631. doi:10.1056/NEJMoa1803537
   PubMed Web of Science ®Google Scholar
• Furuta S, Nakagomi D, Kobayashi Y, et al; for LoVAS Collaborators. Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial. JAMA. 2021;325(21):2178–2187. doi:10.1001/jama.2021.6615
   PubMed Web of Science ®Google Scholar
• Cortazar FB, Muhsin SA, Pendergraft III WF, et al. Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis. Kidney Int Rep. 2017;3(2):394–402. doi:10.1016/j.ekir.2017.11.004
   PubMed Web of Science ®Google Scholar
• McAdoo SP, Medjeral-Thomas N, Gopaluni S, et al. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant. 2019;34(1):63–73. doi:10.1093/ndt/gfx378
   PubMed Web of Science ®Google Scholar
• Bellos I, Michelakis I, Nikolopoulos D. The role of plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Clin Rheumatol. 2021;40(4):1447–1456. doi:10.1007/s10067-020-05390-z
   PubMed Web of Science ®Google Scholar
• Gulati K, Edwards H, Prendecki M, et al. Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2021;100:S0085-2538(21)00859–0. doi:10.1016/j.kint.2021.08.025
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C, Karras A, et al.; for French Vasculitis Study Group. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771–1780. doi:10.1056/NEJMoa1404231
   PubMed Web of Science ®Google Scholar
• Terrier B, Pagnoux C, Perrodeau É, et al.; for French Vasculitis Study Group. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis. 2018;77(8):1150–1156. doi:10.1136/annrheumdis-2017-212768
   PubMed Web of Science ®Google Scholar
• Charles P, Terrier B, Perrodeau É, et al; for French Vasculitis Study Group. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, Phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77:1143–1149. doi:10.1136/annrheumdis-2017-212878
   PubMed Web of Science ®Google Scholar
• Tieu J, Smith R, Basu N, et al. Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. Rheumatology. 2020;59(4):e24–e32. doi:10.1093/rheumatology/kez640
   PubMed Web of Science ®Google Scholar
• Karras A, Pagnoux C, Haubitz M, et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. 2017;76(10):1662–1668. doi:10.1136/annrheumdis-2017-211123
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Akuthota P, Jayne D, et al; for EGPA Mepolizumab Study Team. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921–1932. doi:10.1056/NEJMoa1702079
   PubMed Web of Science ®Google Scholar
• Langford CA, Monach PA, Specks U, et al.; for Vasculitis Clinical Research Consortium. An open-label trial of Abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener’s). Ann Rheum Dis. 2014;73(7):1376–1379. doi:10.1136/annrheumdis-2013-204164
   PubMed Web of Science ®Google Scholar
• US National Library of Medicine. ClinicalTrials.gov; 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT02108860. Accessed March 5, 2022.
   Google Scholar
• Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis. 2008;67(9):1322–1327. doi:10.1136/ard.2007.081661
   PubMed Web of Science ®Google Scholar
• US National Library of Medicine. ClinicalTrials.gov; 2011. Available from: https://clinicaltrials.gov/ct2/show/NCT01405807. Accessed March 5, 2022.
   Google Scholar
• Huizenga N, Zonozi R, Rosenthal J, Laliberte K, Niles JL, Cortazar FB. Treatment of aggressive antineutrophil cytoplasmic antibody-associated vasculitis with eculizumab. Kidney Int Rep. 2019;5(4):542–545. doi:10.1016/j.ekir.2019.11.021
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827–1832. doi:10.1136/ard.2008.101279
   PubMed Web of Science ®Google Scholar
• Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40(2):371–380. doi:10.1002/art.1780400222
   PubMed Web of Science ®Google Scholar
• Basu N, McClean A, Harper L, et al. Explaining fatigue in ANCA-associated vasculitis. Rheumatology. 2013;52(9):1680–1685. doi:10.1093/rheumatology/ket191
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Drucker Y, Cotch MF, Locker GA, Easley K, Kwoh K. Wegener’s granulomatosis: patient-reported effects of disease on health, function, and income. Arthritis Rheum. 1998;41(12):2257–2262. doi:10.1002/1529-0131(199812)41:12<2257::AID-ART22>3.0.CO;2-K
   PubMed Web of Science ®Google Scholar
• Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, et al. Effect of Wegener’s granulomatosis on work disability, need for medical care, and quality of life in patients younger than 40 years at diagnosis. Arthritis Rheum. 2002;47(3):320–325. doi:10.1002/art.10458
   PubMed Web of Science ®Google Scholar
• Weldring T, Smith SM. Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs). Health Serv Insights. 2013;4;6:61–68. doi:10.1016/0006-291x(75)90506-9
   Web of Science ®Google Scholar
• McClure M, Gopaluni S, Wason J, et al. 322. A randomised, double-blind, controlled, mechanistic study of rituximab and belimumab combination therapy in PR3 ANCA-associated vasculitis (COMBIVAS): study protocol. Rheumatology. 2019;58(2):322. doi:10.1093/rheumatology/kez063.046
   Google Scholar
• Robson JC, Milman N, Tomasson G, et al. Exploration, development, and validation of patient-reported outcomes in antineutrophil cytoplasmic antibody-associated vasculitis using the OMERACT process. J Rheumatol. 2015;42(11):2204–2209. doi:10.3899/jrheum.141143
   PubMed Web of Science ®Google Scholar
• Robson JC, Dawson J, Doll H, et al. Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. Ann Rheum Dis. 2018;77:1157–1164. doi:10.1136/annrheumdis-2017-212713
   PubMed Web of Science ®Google Scholar
• Treppo E, Palese A, De Vita S, et al. AB0392 Preliminary validation of the Italian version of ANCA-associated vasculitis Patient-reported Outcome (AAV-PRO ita) questionnaire: fatigue and chronic pain as unmet needs by current treatments. Ann Rheum Dis. 2021;80:1224. doi:10.1136/annrheumdis-2021-eular.2123
   Web of Science ®Google Scholar
• Cheah JTL, Robson JC, Black RJ, et al. The patient’s perspective of the adverse effects of glucocorticoid use: a systematic review of quantitative and qualitative studies. From an OMERACT working group. Semin Arthritis Rheum. 2020;50(5):996–1005. doi:10.1016/j.semarthrit.2020.06.019
   PubMed Web of Science ®Google Scholar
• Black RJ, Robson JC, Goodman SM, et al. A patient-reported outcome measure for effect of glucocorticoid therapy in adults with inflammatory diseases is needed: report from the OMERACT 2016 special interest group. J Rheumatol. 2017;44(11):1754–1758. doi:10.3899/jrheum.161083
   PubMed Web of Science ®Google Scholar
• Bridgewater S, Dawson J, Ndosi M, et al.; for Outcome Measures in Rheumatology (OMERACT) Glucocorticoid Working Group. AB0834 Development of a conceptual framework for a patient reported outcome measure to capture patients’ perception of glucocorticoid therapy during treatment for Rheumatic diseases. Ann Rheum Dis. 2021;80:1441. doi:10.1136/annrheumdis-2021-eular.164
   Web of Science ®Google Scholar
• Fussner LA, Hummel AM, Schroeder DR, et al.; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group. Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheumatol. 2016;68(7):1700–1710. doi:10.1002/art.39637
   PubMed Web of Science ®Google Scholar
• van Dam LS, Dirikgil E, Bredewold EW, et al. PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab. Nephrol Dial Transplant. 2021;36(8):1408–1417. doi:10.1093/ndt/gfaa066
   PubMed Web of Science ®Google Scholar